参一胶囊维持治疗对晚期NSCLC患者NF―κbSTAT3影响回顾性研究.docVIP

参一胶囊维持治疗对晚期NSCLC患者NF―κbSTAT3影响回顾性研究 　　【摘 要】 目的：对晚期非小细胞肺癌（NSCLC）患者进行回顾性分析，探讨参一胶囊维持治疗对患者炎症因子及STAT3 （信号传导蛋白和转录激活物， signal transducers and activators of transcription 3） 和NF-κB（核因子-κB， nuclear factor kappa B）的影响。方法：经一线化疗后取得缓解或稳定的40名晚期NSCLC患者意向性分为治疗组（A组，20人）和对照组（B组，20人）。A组继续服用参一胶囊每天2次，每次20mg，服药至疾病进展或无法耐受；B组未予特殊治疗。分别于第1d、90d采血，酶联免疫吸附测定患者外周血肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）、SATA3和NF-κB。结果：治疗前后比较，治疗组各项炎症指标均未发生明显变化，差异无统计学意义（P0.05）；而对照组的TNF-α、IL-6、SATA3和NF-κB显著上升，差异均具有统计学意义（P0.01）；治疗后两组间比较，对照组TNF-α、IL-6、SATA3和NF-κB显著高于治疗组，差异均具有统计学意义（P0.01）。结论：参一胶囊维持治疗可使晚期NSCLC患者TNF-α、IL-6、SATA3和NF-κB得到有效抑制，进一步提示阻断炎症-癌症正反馈恶性循环可能是参一胶囊维持治疗抑制NSCLC进展的机制之一。 　　【关键词】 参一胶囊；非小细胞肺癌；维持治疗；信号传导蛋白和转录激活物-3；核因子-κB 　　【中图分类号】R734 【文献标志码】 A 【文章编号】1007-8517（2016）12-0121-02 　　Abstract：Objective To retrospectively investigate the influence of Shenyi Capsule maintenance therapy on inflammatory factors， as well as STAT3 （signal transducers and activators of transcription 3） and NF-κB（nuclear factor kappa B） in patients with advanced NSCLC .Method Forty patients with advanced NSCLC， who had become palliative or stable after first-line chemotherapy ， were intentionally assigned to treatment group and control group equally. Shenyi Capsule was given to treatment group （20mg p.o.， bid） until appearance of deterioration or intolerance， while no special treatment was given to control group. Tumor necrosis factor α （TNF-α）， interleukin-6（IL-6）， STAT3 and NF-κB were tested by blood specimens taken respectively on 1st day and 90th day with ELISA test kit. Results In treatment group， there were no statistical differences （P0.05） in the level of all the four indexes between 1th day and 90th day. In control group， however， TNF-α， IL-6， STAT3 and NF-κB altogether increased significantly （P0.01） after 90days. Furthermore， the level of TNF-α， IL-6， STAT3 and NF-κB in treatment group were also lower （P0.01） than control group on 90th day. Conclusion Shenyi Capsule maintenance therapy could inhibit the expression of TNF-α， IL-6 STAT3 a